The total ORR to EGFR-TKIs was 2.3% (4/175) in KRAS mutant patients and 13.6% (101/740) in KRAS and EGFR wild-type patients based on 14 studies [9-11, 18, 19, 21, 22, 31, 32, 34, 35, 40, 42, 51] conducted in stage IIIb-IV unresectable NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.